- CMR Surgical, the Company that has developed and is commercialising the next-generation surgical robot, Versius, today announces Massimiliano Colella, a seasoned MedTech leader, has been appointed Interim Chief Executive Officer
- Massimiliano assumes the role as the Company continues to accelerate its journey to bring minimal access surgery to more patients around the world, with Versius having already been used in over 26,000 surgical procedures, across seven surgical specialties, including performing complex surgeries such as low anterior resections and partial nephrectomies
- After four decades in the MedTech industry, Supratim Bose has stepped down as CEO due to personal reasons, in order to be able to return to Singapore. He takes up the role of Vice-Chairman of the Board to continue to support CMR to bring Versius to more patients around the world
Massimiliano originally joined CMR as Chief Commercial Officer in 2023, helping to drive growth in installed base and bring Versius to more hospitals around the world. Today, Versius has been used to perform over 26,000 robotic-assisted minimally invasive surgeries globally.
Massimiliano joined from Evercare Group, a leading hospital group, where he served as Group Chief Executive Officer and Board member. In this role, he oversaw 30 hospitals, 16 clinics, and over 100 diagnostic centers. He brings more than 30 years of senior healthcare leadership experience having held senior executive roles for Johnson & Johnson (J&J) and Smith & Nephew. At Johnson & Johnson, Massimiliano, amongst several roles, was responsible for all Medical Device Companies within the Central Eastern Europe and Emerging Markets regions.
Supratim Bose has brought to CMR significant experience in the MedTech industry, supporting the business on its journey to bring minimal access surgery to more patients around the world. Supratim will continue to bring his extensive MedTech experience to serve CMR in his role on the Board.
Dan Moore, Chairman at CMR Surgical commented: “I am pleased to welcome Massimiliano in his new role as Interim CEO. Given his significant MedTech leadership experience, and passion for CMR and the surgical robotics industry, we are pleased to have someone of his stature take over the leadership of CMR. We look forward to working closely with Massimiliano to help CMR transform surgery for patients around the world as we open new markets and launch further Versius product advancements. As a Board, we continue to support CMR for the long-term to ensure the Company can reach its full potential. I would like to thank Supratim for his extensive contributions to CMR as CEO, and we look forward to continuing to work with him on the Board.”
Massimiliano Colella, Interim Chief Executive Officer at CMR Surgical commented: “I am honoured to lead CMR and make sure we can seize our opportunity to offer hospitals and patients choice when deciding to start a surgical robotics programme. I have worked for large medical device businesses, and a hospital group, but this is a truly unique opportunity to lead a Company that has exceptional people, and an excellent product. Having conducted over 26,000 procedures, the value of Versius as a compact, digitally driven system has been demonstrated globally and gives us an excellent base to build on from here. We will always continue to focus on our customers, and by doing so I am confident that CMR and Versius will be able to achieve its mission of transforming surgery for patients around the world.”
Supratim Bose, Outgoing CEO and Vice-Chairman of the Board at CMR Surgical commented: “I have worked with reputed organisations in the MedTech industry for over four decades and I can say it has been a privilege to lead the CMR organisation. It is now time for me to transition into a Board role as Vice-Chairman of the CMR Board, and Massimiliano is the best person to take over my responsibility. I am pleased that we have someone of his calibre to lead the business as we continue our growth journey. With Massimiliano leading the business, a disruptive product, and exceptional people in the business, I am confident that CMR can transform surgery for good for all surgeons and patients around the world.”
